ATLANTA, Ga.--(BUSINESS WIRE)--MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that it has appointed Ernst & Young as the Company’s new auditor to further support global expansions targeting the $6 billion cardiovascular stent market.
